Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics' stock has experienced a price decline, a 1-20 reverse stock split on June 9th, 2025, and a discounted share offering on August 14, 2025. In January 2026, the company discontinued its lead program, BDC-1001, and reduced its workforce by approximately 50%. The company reported Q3 2025 earnings with an EPS of -$3.72 and revenue of $2.17 million, and Q1 2025 collaboration revenue of $1.2 million. For full-year 2024, the company reported collaboration revenue of $7.7 million and an operational loss of $73.0 million.

Traditional demand seasonality does not apply to Bolt Biotherapeutics, as demand for its pipeline products is driven by clinical trial progress, regulatory approvals, and unmet medical needs in oncology. Revenue is primarily derived from collaboration agreements rather than direct sales.

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company in Redwood City, California, focused on developing immuno-oncology therapies using its Boltbody™ ISAC platform. The company's pipeline includes BDC-3042, a Dectin-2 agonist in Phase 1 trials, and BDC-4182, a next-generation Boltbody ISAC expected to enter clinical trials in Q2 2025. Bolt Biotherapeutics collaborates with companies like Toray Industries and Bristol-Myers Squibb.

Bolt Biotherapeutics, Inc. is headquartered in Redwood City, California, located in the San Francisco Bay Area.

Bolt Biotherapeutics' brand reputation has been impacted by concerns about its pipeline and financial health. The discontinuation of BDC-1001, workforce reduction, and stock price decline have negatively affected its standing. Despite advancing next-generation candidates and reporting positive preclinical data, the overall sentiment is cautious.

Bolt Biotherapeutics, Inc. has significant institutional ownership, including Vivo Capital, LLC, Sofinnova Investments, Inc., and Vanguard Total Stock Market Index Fund Investor Shares (VTSMX). Individual owners include insiders such as Edgar Engleman and William P Quinn.